2024-04-05 06:42:07 ET
Summary
- Boston Scientific expects 8-10% sales growth in their 2024-2026 guidance, which already includes short-term upsides such as FARAPULSE’s recent FDA approval.
- The legal clash between Axonics and Medtronic may endanger Boston Scientific's ability to commercialize Axonics' products in the near future.
- BSX is currently trading at historically high prices. Given the limited upside and the recent share price rally, Boston Scientific is overvalued.
Thesis
Boston Scientific Corporation ( BSX ) delivered good results in their FY2023 report , within its 2024-2026 guidance the company expects 8-10% sales growth which already accounts with the recent FDA approval of FARAPULSE as well as a revenue increase derived from the Axonics' deal from 2025....
Read the full article on Seeking Alpha
For further details see:
Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash